A-TANGO highlights at EASL Congress 2023
The A-TANGO consortium performs Phase 2 clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. This novel combinatorial therapy is called G-TAK. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and…